Journal News

Mechanisms of a gut bacterium – and how to stop them

Aswathy Rai
Oct. 10, 2023

The human gastrointestinal tract is one of the most diverse and complex ecosystems, comprising trillions of microbes. Bile acids produced by the liver and secreted into the intestines not only aid in the digestion of food but also protect against pathogenic microorganisms in the gut. To survive the hostile environment of the GI tract, bacteria must develop strategies for resistance.

Vibrio parahaemolyticus, a Gram-negative bacterium that causes food-borne diseases can sense and use bile acids as a signal to activate harmful toxins that cause diarrhea. Understanding how pathogenic bacteria evade host defense mechanisms is critical in developing new treatments to prevent or cure gastrointestinal diseases.

Kim Orth, at the University of Texas Southwestern Medical Center, leads a team that researches virulence mechanisms used by V. parahaemolyticus to survive in the GI tract. In a recent study published in the Journal of Biological Chemistry, graduate student Angela Zhou and colleagues show how V. parahaemolyticus differentially senses bile acids to activate toxin production.

A major pathogenic factor of the organism is a type III secretion system called T3SS2. T3SS2 comprises bacterial structures that help inject effector proteins that enable the V. parahaemolyticus to invade the host and establish infection. “When Vibrio parahaemolyticus is ingested and enters the intestines, it senses bile acids and activates the T3SS2,” Orth said. “The T3SS2 secretion system injects toxins from the bacteria into cells lining the intestine, causing disease.”

Two membrane proteins in the bacteria, VtrA and Vtr-C, form a complex to control production of the T3SS2. The VtrA–VtrC responds to the host GI tract bile acids to induce VtrB, another membrane-bound protein that activates the T3SS2. Bile acids, such as taurodeoxycholate or TDC, trigger VtrB expression and T3SS2 activation, while others like chenodeoxycholate, or CDC, do not.

Using X-ray crystallography, isothermal titration calorimetry and green fluorescent protein reporter assays, Zhou and colleagues determined why TDC, but not CDC, activates the T3SS2 upon binding VtrA–VtrC. They found that the differences in sensing bile acids were due to the subtle differences in the molecular structures of CDC and TDC. They showed that two amino acids, histidine50 and serine123, were vital for determining whether TDC and not CDC activates the T3SS2.

“These bile acids act like a card reader for a locked door,” Orth said. “If a person has access to the room behind the door, inserting their card into the card reader will unlock the door, and if a person who does not have access inserts their card, the door will remain locked,” Orth added.

The team was excited to find that CDC also binds to VtrA–VtrC within the same pocket in the protein as TDC. However, a closer examination of the structure's atomic-level interactions showed that CDC and TDC bind to VtrA–VtrC differently.

“Our research reveals how enteric bacteria use environmental cues to cause gastrointestinal disease and provides clues on why certain people are more susceptible to disease than others,” Orth said. "Researchers recently found bile acids are modified by good bacteria that live in the intestines, which can protect against harmful bacteria by changing the makeup of the bile acid pool in the intestines.”

The researchers performed the X-ray crystallography and ITC experiments on only a part of the VtrA and VtrC proteins, the periplasmic domain. In the future, the team will focus on determining the molecular mechanism of differential activation of the T3SS2 by TDC and CDC using the entire VtrA and VtrC proteins.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Aswathy Rai

Aswathy N. Rai is an assistant teaching professor and undergraduate coordinator at Mississippi State University's department of biochemistry, molecular biology, entomology and plant pathology.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The quest to treat and cure xerostomia
Interview

The quest to treat and cure xerostomia

July 23, 2024

Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.

There's more to blue cheese than just the stench
News

There's more to blue cheese than just the stench

July 21, 2024

Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.

Engineering cells to broadcast their behavior can help scientists study their inner workings
News

Engineering cells to broadcast their behavior can help scientists study their inner workings

July 20, 2024

Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.

From the journals: JBC
Journal News

From the journals: JBC

July 19, 2024

Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.